As previously reported, Guggenheim upgraded Surrozen (SRZN) to Buy from Neutral with a $45 price target Recent Phase 1b data for SZN-043, the company’s lead asset for liver disease, was “encouraging,” says the analyst, who is “interested to see if the company can maintain below 15-20% 30-day mortality at higher doses.” Additional data are expected in the first half of 2025, the analyst noted.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SRZN:
Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.
Report an Issue